Cisplatin (Platinol ®)
Novel and Future Treatment Options in Mesothelioma: A Systematic Review
International Journal of Molecular Sciences 2022 February 10 [Link] Danijela Štrbac, Vita Dolžan Abstract Mesothelioma is a rare tumor, frequently associated with asbestos exposure, arising from pleura and peritoneum. Traditionally, diagnosis and treatment have been difficult in a clinical setting. The treatment is based on a trimodal approach involving surgery, chemotherapy, and radiotherapy. The introduction…
Read MoreDynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
BMC Cancer 2022 February 20 [Link] Martina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popovič Abstract Background: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to…
Read MoreAbemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
The Lancet Oncology 2022 February 11 [Link] Dean A Fennell, Amy King, Seid Mohammed, Alastair Greystoke, Sarah Anthony, Charlotte Poile, Nada Nusrat, Molly Scotland, Vina Bhundia, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Amrita Bajaj, Cathy Richards, Peter Wells-Jordan, Anne Thomas, MiST2 study group Abstract Background: Genetically…
Read MoreCisplatin-Chelated Iminodiacetic Acid-Conjugated Hyaluronic Acid Nanogels for the Treatment of Malignant Pleural Mesothelioma in Mice
Molecular Pharmaceutics 2022 February 10 [Link] Yuki Amano, Kazuma L Sakura, Seiichi Ohta, Taichi Ito Abstract Malignant pleural mesothelioma (MPM) is one of the intractable cancers that require a more effective therapeutic strategy for clinical practice. Hyaluronic acid (HA) nanogels were prepared by the chelation of cisplatin (CDDP) with different molecular weights of iminodiacetic acid-conjugated…
Read MoreFirst-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Annals of Oncology 2022 February 3 [Link] S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, M A Kaplan, T Talbot, I Monnet, S Hiret, P Baas, A K Nowak, N Fujimoto, A S Tsao, A S Mansfield, S Popat, X Zhang, N Hu, D Balli, T Spires, G Zalcman Abstract Background: In the…
Read MoreNew Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Journal of Clinical Oncology 2022 January 5 [Link] Anne S Tsao, Harvey I Pass, Andreas Rimner, Aaron S Mansfield Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device…
Read MoreImmunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Therapeutic Advances In Medical Oncology 2021 December 10 [Link] Valérie Gounant, Solenn Brosseau, Gérard Zalcman Abstract Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1,…
Read MoreDurvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Nature Medicine 2021 November [Link] Patrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E Dahlberg, Hedy L Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N Smith, Archana Balan, James R White, Christopher Cherry, I K Ashok Sivakumar, Xiaoshan M Shao, Hok Yee Chan, Dipika Singh,…
Read MoreJME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Journal for Immunotherapy of Cancer 2021 October [Link] Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto Abstract Background: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). Patients and methods:…
Read MoreQuinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations
Frontiers in Pharmacology 2021 September [Link] Derek B Oien, Sayantani Sarkar Bhattacharya, Jeremy Chien, Julian Molina, Viji Shridhar Abstract Mesothelioma is a rare cancer with disproportionately higher death rates for shipping and mining populations. These patients have few treatment options, which can be partially attributed to limited chemotherapy responses for tumors. We initially hypothesized that…
Read More